Case records of the Massachusetts General Hospital. Case 26-2005. A 48-year-old man with sudden loss of consciousness while jogging.

[1]  B. Maron,et al.  26th Bethesda conference: recommendations for determining eligibility for competition in athletes with cardiovascular abnormalities. Task Force 3: hypertrophic cardiomyopathy, myocarditis and other myopericardial diseases and mitral valve prolapse. , 1994, Medicine and science in sports and exercise.

[2]  H. G. Martin,et al.  Prospective evaluation of syncope in patients presenting to the emergency department , 1984 .

[3]  Barry J Maron,et al.  American College of Cardiology/European Society of Cardiology clinical expert consensus document on hypertrophic cardiomyopathy. A report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents and the European Society of Cardiology Committee for Practice G , 2003, Journal of the American College of Cardiology.

[4]  C. Semsarian,et al.  Long-term follow-up of implantable cardioverter defibrillator therapy for hypertrophic cardiomyopathy. , 2004, The American journal of cardiology.

[5]  P. Elliott,et al.  Non-sustained ventricular tachycardia in hypertrophic cardiomyopathy: an independent marker of sudden death risk in young patients. , 2003, Journal of the American College of Cardiology.

[6]  P. Safar,et al.  Cerebral resuscitation potentials for cardiac arrest. , 2002, Critical care medicine.

[7]  B. Maron,et al.  Magnitude of left ventricular hypertrophy and risk of sudden death in hypertrophic cardiomyopathy. , 2000, The New England journal of medicine.

[8]  J. Hunter.  The works of John Hunter , 1981 .

[9]  U. Sigwart.  Non-surgical myocardial reduction for hypertrophic obstructive cardiomyopathy , 1995, The Lancet.

[10]  W. McKenna,et al.  Hypertrophic cardiomyopathy — pathology and pathogenesis , 1995, Histopathology.

[11]  M. Brignole,et al.  Diagnostic value of history in patients with syncope with or without heart disease. , 2001, Journal of the American College of Cardiology.

[12]  D. Fatkin,et al.  Molecular mechanisms of inherited cardiomyopathies. , 2002, Physiological reviews.

[13]  L. Caplan,et al.  Avoiding pitfalls in the diagnosis of subarachnoid hemorrhage. , 2000, The New England journal of medicine.

[14]  W. Mckenna,et al.  The management of hypertrophic cardiomyopathy. , 1997, The New England journal of medicine.

[15]  Ming-Hui Chen,et al.  Incidence and prognosis of syncope , 2003 .

[16]  W. Henry,et al.  Operative Treatment in Hypertrophic Subaortic Stenosis: Techniques, and the Results of Pre and Postoperative Assessments in 83 Patients , 1975, Circulation.

[17]  M. Quiñones,et al.  Simvastatin Induces Regression of Cardiac Hypertrophy and Fibrosis and Improves Cardiac Function in a Transgenic Rabbit Model of Human Hypertrophic Cardiomyopathy , 2001, Circulation.

[18]  B. Maron,et al.  Epidemiology of hypertrophic cardiomyopathy-related death: revisited in a large non-referral-based patient population. , 2000, Circulation.

[19]  K. P. Carney,et al.  Relationship of race to sudden cardiac death in competitive athletes with hypertrophic cardiomyopathy. , 2003, Journal of the American College of Cardiology.

[20]  R. Nishimura,et al.  Clinical practice. Hypertrophic obstructive cardiomyopathy. , 2004, The New England journal of medicine.

[21]  H. G. Martin,et al.  Prospective evaluation of syncope. , 1984, Annals of emergency medicine.

[22]  George Tomlinson,et al.  Is this patient dead, vegetative, or severely neurologically impaired? Assessing outcome for comatose survivors of cardiac arrest. , 2004, JAMA.

[23]  M. Entman,et al.  Aldosterone, Through Novel Signaling Proteins, Is a Fundamental Molecular Bridge Between the Genetic Defect and the Cardiac Phenotype of Hypertrophic Cardiomyopathy , 2004, Circulation.

[24]  M. Link,et al.  Efficacy of implantable cardioverter-defibrillators for the prevention of sudden death in patients with hypertrophic cardiomyopathy. , 2000, The New England journal of medicine.

[25]  Michael J Ackerman,et al.  Recommendations for physical activity and recreational sports participation for young patients with genetic cardiovascular diseases. , 2004, Circulation.

[26]  T. Nakano,et al.  Prognosis of completely asymptomatic adult patients with hypertrophic cardiomyopathy. , 1999, Journal of the American College of Cardiology.

[27]  P. Elliott,et al.  Sudden death in hypertrophic cardiomyopathy: identification of high risk patients. , 2000, Journal of the American College of Cardiology.

[28]  S. Betocchi,et al.  Aetiology and pathogenesis of hypertrophic cardiomyopathy , 2002, Acta paediatrica (Oslo, Norway : 1992). Supplement.

[29]  S. Silvers,et al.  Clinical policy: critical issues in the evaluation and management of patients presenting with syncope. , 2001, Annals of emergency medicine.

[30]  E F Cook,et al.  Evaluation and outcome of emergency room patients with transient loss of consciousness. , 1982, The American journal of medicine.

[31]  Christian Lovis,et al.  Prospective evaluation of patients with syncope: a population-based study. , 2001, The American journal of medicine.

[32]  S. Hughes.  The pathology of hypertrophic cardiomyopathy , 2004, Histopathology.

[33]  W. Kapoor,et al.  CLINICAL GUIDELINE: Diagnosing Syncope: Part 1: Value of History, Physical Examination, and Electrocardiography , 1997, Annals of Internal Medicine.

[34]  G O Barnett,et al.  Patients with syncope admitted to medical intensive care units. , 1982, JAMA.

[35]  M. Frenneaux.  Assessing the risk of sudden cardiac death in a patient with hypertrophic cardiomyopathy , 2004, Heart.

[36]  M. Entman,et al.  Angiotensin II Blockade Reverses Myocardial Fibrosis in a Transgenic Mouse Model of Human Hypertrophic Cardiomyopathy , 2001, Circulation.

[37]  W. Roberts,et al.  Sudden Death in Young Athletes , 1980, Circulation.

[38]  Lennart Bergfeldt,et al.  DIFFERENTIAL DIAGNOSIS OF CARDIOGENIC SYNCOPE AND SEIZURE DISORDERS , 2003, Heart.

[39]  W J McKenna,et al.  Hypertrophic cardiomyopathy: the interrelation of disarray, fibrosis, and small vessel disease , 2000, Heart.

[40]  A. Blamire,et al.  Hypertrophic cardiomyopathy due to sarcomeric gene mutations is characterized by impaired energy metabolism irrespective of the degree of hypertrophy. , 2003, Journal of the American College of Cardiology.

[41]  B. Maron,et al.  Cardiac disease in young trained athletes. Insights into methods for distinguishing athlete's heart from structural heart disease, with particular emphasis on hypertrophic cardiomyopathy. , 1995, Circulation.

[42]  B. Maron.  Sudden death in young athletes. , 1980, The New England journal of medicine.